Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer

PURPOSE: Mutations in the RET proto-oncogene and vascular endothelial growth factor receptor (VEGFR) activity are critical in the pathogenesis of medullary thyroid cancer (MTC). Sorafenib, a multikinase inhibitor targeting Ret and VEGFR, showed antitumor activity in preclinical studies of MTC. PATIE...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Lam, Elaine T., Ringel, Matthew D., Kloos, Richard T., Prior, Thomas W., Knopp, Michael V., Liang, Jiachao, Sammet, Steffen, Hall, Nathan C., Wakely, Paul E., Vasko, Vasyl V., Saji, Motoyasu, Snyder, Pamela J., Wei, Lai, Arbogast, Daria, Collamore, Minden, Wright, John J., Moley, Jeffrey F., Villalona-Calero, Miguel A., Shah, Manisha H.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2010
Teme:
Original Reports
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2881718/
https://ncbi.nlm.nih.gov/pubmed/20368568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.25.0068
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki